Effect Of 4 ' Galactooligosaccharide On Constipation Symptoms

dc.creatorBeleli
dc.creatorCelia A. V.; Antonio
dc.creatorMaria A. R. G. M.; dos Santos
dc.creatorRosangela; Pastore
dc.creatorGlaucia M.; Lomazi
dc.creatorElizete A.
dc.date2015-NOV-DEC
dc.date2016-06-07T13:19:08Z
dc.date2016-06-07T13:19:08Z
dc.date.accessioned2018-03-29T01:39:21Z
dc.date.available2018-03-29T01:39:21Z
dc.identifier
dc.identifierEffect Of 4 ' Galactooligosaccharide On Constipation Symptoms. Soc Brasil Pediatria, v. 91, p. 567-573 NOV-DEC-2015.
dc.identifier0021-7557
dc.identifierWOS:000366956100010
dc.identifier10.1016/j.jped.2015.01.010
dc.identifierhttp://www.sciencedirect.com/science/article/pii/S0021755715001023
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/242632
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1306330
dc.descriptionObjective: Fructooligosacharides and galactooligosacharides soften fecal bolus and increase frequency of depositions when added to infant formula. This study aimed to determine the effects of galactooligosaccharide in pediatric patients with chronic constipation. Methods: From 2010 to 2012, 20 constipated patients (4-16 years of age) attended to at a primary healthcare unit were enrolled in a double-blinded, placebo-controlled crossover trial. Eleven children ingested galactooligosaccharide (1.7 g) for 30 days, followed by a 15-day washout period, and a 30-day period of placebo (maltodextrin). Nine patients ingested maltodextrin for 30 days, followed by 15-day washout period, and galactooligosaccharide (1.7 g) for 30 days. Constipation symptoms were considered as primary outcomes: bowel movements/week, straining during defecation, and stool consistency. Outcome symptoms were ranked according to a numerical scale elaborated for this study. Data were recorded at baseline, and on days 15 and 30 of each 30-day crossover period. Repeated-measures analysis of variance (ANOVA) was used to analyze symptoms along time. Results: At baseline, there was no significant difference in symptoms severity between groups (p = 0.45). Galactooligosaccharide ingestion was related to increase of the bowel movement frequency, p < 0.0001; relief of defecation straining, p < 0.0001; and decrease in stool consistency, p = 0.0014, compared to placebo ingestion. Patients reported no side effects from galactooligosaccharide. Conclusion: Galactooligosaccharide was effective at improving clinical symptoms in this group of constipated children. (C) 2015 Sociedade Brasileira de Pediatria. Published by Elsevier Editora Ltda. All rights reserved.
dc.description91
dc.description6
dc.description
dc.description567
dc.description573
dc.description
dc.description
dc.description
dc.languageen
dc.publisherSOC BRASIL PEDIATRIA
dc.publisher
dc.publisherRIO DE JANEIRO, RJ
dc.relationJORNAL DE PEDIATRIA
dc.rightsfechado
dc.sourceWOS
dc.subjectChain Fructo-oligosaccharides
dc.subjectGalacto-oligosaccharides
dc.subjectChildhood Constipation
dc.subjectTerm Infants
dc.subjectFecal Bifidobacteria
dc.subjectFormula
dc.subjectChildren
dc.subjectGalactooligosaccharides
dc.subjectPolydextrose
dc.subjectMixture
dc.titleEffect Of 4 ' Galactooligosaccharide On Constipation Symptoms
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución